Therapy for Osteosarcoma
Top Cited Papers
- 1 January 2008
- journal article
- review article
- Published by Springer Science and Business Media LLC in Pediatric Drugs
- Vol. 10 (5), 315-327
- https://doi.org/10.2165/00148581-200810050-00005
Abstract
Osteosarcoma is the most common malignant primary bone tumor in children and adolescents. Current optimal treatment for osteosarcoma consists of multi-agent chemotherapy and aggressive surgical resection of all sites of disease involvement. The current national and international cooperative trial for patients with newly diagnosed osteosarcoma builds upon the backbone of cisplatin, doxorubicin, and methotrexate. This protocol is designed to clarify whether (i) the addition of ifosfamide and etoposide to postoperative chemotherapy with cisplatin, doxorubicin, and methotrexate improves the event-free survival and overall survival for patients with resectable osteosarcoma and a poor histologic response to 10 weeks of preoperative chemotherapy; and (ii) the addition of pegylated interferon-α-2b as maintenance therapy after postoperative chemotherapy with cisplatin, doxorubicin, and methotrexate improves the event-free survival and overall survival for patients with resectable osteosarcoma and a good histologic response to 10 weeks of preoperative chemotherapy. However, the optimal treatment strategy (or strategies) for patients with relapsed or metastatic disease has yet to be defined. This remains one of the persistent challenges in the treatment of osteosarcoma. Recent therapeutic advances have focused on circumventing chemotherapy resistance mechanisms, incorporation of non-classical agents into upfront therapy, targeting of the tumor micro-environment, and investigating the role of novel delivery mechanisms. In patients with localized disease the 5-year survival rate is at least 70%; patients with metastatic or recurrent disease have <20% chance of long-term survival despite aggressive therapies. These figures have changed little in the past 2 decades. This review focuses on the current therapy for osteosarcoma, and highlights emerging strategies that will hopefully change the outlook for patients with this disease.Keywords
This publication has 101 references indexed in Scilit:
- Post-translational modification of p53 in tumorigenesisNature Reviews Cancer, 2004
- Pattern of disease recurrence and prognostic factors in patients with osteosarcoma treated with contemporary chemotherapyCancer, 2003
- Reduced folate carrier protein expression in osteosarcomaCancer, 2003
- Molecular Mechanisms of Bone Metastasis and Therapeutic ImplicationsClinical Orthopaedics and Related Research, 2003
- Does the histological subtype of high-grade central osteosarcoma influence the response to treatment with chemotherapy and does it affect overall survival? A study on 570 patients of two consecutive trials of the European Osteosarcoma IntergroupEuropean Journal Of Cancer, 2002
- Redundancy of autocrine loops in human osteosarcoma cellsInternational Journal of Cancer, 1999
- Expression of insulin-like growth factor receptor, IGF-1, and IGF-2 in primary and metastatic osteosarcomaJournal of Surgical Oncology, 1998
- CDKN2A Gene Deletions and Loss of p16 Expression Occur in Osteosarcomas That Lack RB AlterationsThe American Journal of Pathology, 1998
- Insulinlike Growth Factor I: A Potent Mitogen for Human Osteogenic SarcomaJNCI Journal of the National Cancer Institute, 1990
- The Effect of Adjuvant Chemotherapy on Relapse-Free Survival in Patients with Osteosarcoma of the ExtremityNew England Journal of Medicine, 1986